NONMEM Users Network Archive

Hosted by Cognigen

Webinar: QSP model of Schizophrenia

From: Rebecca Baillie <rbaillie>
Date: Tue, 2 Jun 2020 16:07:42 +0000

Development of a QSP Platform to Quantify Benefits of DAAO Inhibition in Sc=

Sergio Iadevaia, PhD
Scientific Director QSP, Pharmacometrics and Data Analysis at Takeda
Wednesday June 17, 2020, 12:00 to 1:00 pm EDT
Register for free at

Hypofunctioning of the N-methyl-d-aspartate receptor (NMDAR) and reduction =
of the NMDAR primary coagonist, d-serine, have been associated with the pat=
hophysiology of schizophrenia. Inhibition of d-amino acid oxidase (DAAO) re=
sults in increased d-serine and may lead to improvement in negative symptom=
s of schizophrenia. TAK-831, a highly selective and potent inhibitor of DAA=
O, increased d-serine levels in the cerebellum of mice and demonstrated a p=
ositive effect on cognition and social interaction in rodent cognition and =
behavioral models.

In collaboration with scientists from Rosa, Takeda developed a mechanistic =
platform that includes plasma, cerebrospinal fluid and brain compartments, =
the primary site of DAAO inhibition and a cerebellar tripartite synapse for=
 modulation of NMDAR signaling, to enable quantitative assessment of the cl=
inical benefits of TAK-831.

This webinar will discuss how the platform was developed, the result that i=
t yielded, and the impact it had on clinical decision making.

Received on Tue Jun 02 2020 - 12:07:42 EDT

The NONMEM Users Network is maintained by ICON plc. Requests to subscribe to the network should be sent to:

Once subscribed, you may contribute to the discussion by emailing: